Predictive value of baseline metabolic tumor volume in early-stage favorable Hodgkin Lymphoma – Data from the prospective, multicenter phase III HD16 trial

被引：0
|
作者：
Lutz van Heek
Colin Stuka
Helen Kaul
Horst Müller
Jasmin Mettler
Felicitas Hitz
Christian Baues
Michael Fuchs
Peter Borchmann
Andreas Engert
Markus Dietlein
Conrad-Amadeus Voltin
Carsten Kobe
机构：
[1] University of Cologne,Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne
[2] University of Cologne,First Department of Internal Medicine and German Hodgkin Study Group (GHSG), Center for Integrated Oncology Aachen – Bonn – Cologne – Düsseldorf (CIO ABCD), Faculty of Medicine and University Hospital Cologne
[3] Swiss Group for Clinical Cancer Research,Department of Medical Oncology and Haematology
[4] Kantonsspital St.Gallen,Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and UniversityHospital Cologne
[5] University of Cologne,undefined
来源：
BMC Cancer | / 22卷
关键词：
Hodgkin lymphoma; Metabolic tumor volume; FDG PET; Response prediction;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Positron emission tomography guided omission of radiotherapy in early-stage unfavorable Hodgkin Lymphoma: Final results of the international, randomized Phase III HD17 trial by the German Hodgkin Study Group
    Borchmann, P.
    Kobe, C.
    Pluetschow, A.
    Greil, R.
    Meissner, J.
    Topp, M. S.
    Ostermann, H.
    Dierlamm, J.
    Mohm, J.
    Thiemer, J.
    Soekler, M.
    Kerkhoff, A.
    Ahlborn, M.
    Halbsguth, T.
    Martin, S.
    Keller, U.
    Balabanov, S.
    Pabst, T.
    Vogelhuber, M.
    Huettmann, A.
    Wilhem, M.
    Zijlstra, J. M.
    Moccia, A.
    Broeckelmann, P. J.
    von Tresckow, B.
    Fuchs, M.
    Eich, H.
    Baues, C.
    Hallek, M.
    Diehl, V
    Dietlein, M.
    Engert, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 32 - 32
  • [22] Results of a prospective clinical trial for VAMP alone without irradiation for pediatric favorable, early-stage Hodgkin lymphoma patients who achieve an early complete response.
    Metzger, M.
    Weinstein, H. J.
    Hudson, M. M.
    Billett, A.
    Larsen, E. C.
    Friedmann, A. M.
    Donaldson, S. S.
    Krasin, M. J.
    Kun, L. E.
    Marcus, K. C.
    Yock, T. I.
    Tarbell, N.
    Billups, C.
    Wu, J.
    Link, M. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Stellenwert der Radiotherapie bei Morbus Hodgkin in intermediären StadienErgebnisse der HD17-Studie (GHSG)Radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17)A multicentre phase III trial
    Christoph Süß
    Oliver Kölbl
    Strahlentherapie und Onkologie, 2021, 197 : 946 - 949
  • [24] Major Pathological Response as a Predictive Value of Survival in Early-Stage NSCLC After Chemotherapy: Cohort of NATCH Phase III Trial
    Carcereny, E.
    Martinez, A.
    Mate, J. L.
    Sansano, J.
    Pardo, N.
    Estival, A.
    Navarro, A.
    Martinez De Castro, A.
    Zeron-Medina, J.
    Romero Vielva, L.
    Moran, T.
    Cedres, S.
    Felip, E.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1982 - S1982
  • [25] Prognosis value of baseline total metabolic tumor volume (TMTV) in advanced Hodgkin lymphoma (HL) : Ancillary study of AHL2011 LYSA trial
    Kanoun, S.
    Berriolo-Riedinger, A.
    Tal, I.
    Edeline, V.
    Cottereau, A.
    Brice, P.
    Bouabdallah, R.
    Salles, G.
    Stamatoullas, A.
    Dupuis, J.
    Andre, M.
    Mounier, N.
    Ferme, C.
    Meignan, M.
    Casasnovas, R.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S125 - S126
  • [26] More Chemotherapy Does Not Obviate the Need for Radiation Therapy (RT): Treatment for Early-Stage Favorable Hodgkin Lymphoma According to the HD10 Trial Compared With Chemotherapy Alone
    Pinnix, C. C.
    Abou Yehia, Z.
    Smith, G. L.
    Milgrom, S. A.
    Ho, J. C.
    Reddy, J.
    Gunther, J. R.
    Akhtari, M.
    Osborne, E. M.
    Medeiros, L. J.
    Fanale, M.
    Dabaja, B.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : E489 - E490
  • [27] RAPID Trial Demonstrates Low Positive Predictive Value of Interim FDG-PET in Early-stage Hodgkin Lymphoma After Three Cycles of ABVD
    Fulbright, Joy M.
    Williams, Sarah E.
    Pahud, Barbara A.
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2016, 38 (02) : 165 - 165
  • [28] Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2
    Stuver, Robert
    Michaud, Laure
    Casulo, Carla
    Advani, Ranjana H.
    Budde, Elizabeth L.
    Barr, Paul M.
    Batlevi, Connie Lee
    Caron, Philip C.
    Constine, Louis S.
    Dandapani, Savita
    Drullinsky, Pamela
    Friedberg, Jonathan W.
    Grieve, Clare
    Hamilton, Audrey
    Hamlin, Paul A.
    Hoppe, Richard
    Horwitz, Steven M.
    Khan, Niloufer
    Matasar, Matthew J.
    Noy, Ariela
    Palomba, M. Lia
    Schoder, Heiko
    Straus, David J.
    Vemuri, Shreya
    Yahalom, Joachim
    Yang, Joanna C.
    Younes, Anas
    Zelenetz, Andrew D.
    Moskowitz, Craig H.
    Kumar, Anita
    Moskowitz, Alison J.
    BLOOD, 2022, 140 : 1756 - 1758
  • [29] Involved-Field Radiation Therapy Prevents Recurrences in the Early Stages of Hodgkin Lymphoma in PET-Negative Patients After ABVD Chemotherapy: Relapse Analysis of GHSG Phase 3 HD16 Trial
    Baues, Christian
    Goergen, Helen
    Fuchs, Michael
    Rosenbrock, Johannes
    Celik, Eren
    Eich, Hans
    Kobe, Carsten
    Voltin, Conrad-Amadeus
    Engert, Andreas
    Borchmann, Peter
    Marnitz, Simone
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 111 (04): : 900 - 906
  • [30] PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17) : a multicentre, open-label, randomised, phase 3 trial
    Borchmann, Peter
    Plutschow, Annette
    Kobe, Carsten
    Greil, Richard
    Meissner, Julia
    Topp, Max S.
    Ostermann, Helmut
    Dierlamm, Judith
    Mohm, Johannes
    Thiemer, Julia
    Sokler, Martin
    Kerkhoff, Andrea
    Ahlborn, Miriam
    Halbsguth, Teresa, V
    Martin, Sonja
    Keller, Ulrich
    Balabanov, Stefan
    Pabst, Thomas
    Vogelhuber, Martin
    Huttmann, Andreas
    Wilhelm, Martin
    Zijlstra, Josee M.
    Moccia, Alden
    Kuhnert, Georg
    Brockelmann, Paul J.
    von Tresckow, Bastian
    Fuchs, Michael
    Klimm, Beate
    Rosenwald, Andreas
    Eich, Hans
    Baues, Christian
    Marnitz, Simone
    Hallek, Michael
    Diehl, Volker
    Dietlein, Markus
    Engert, Andreas
    LANCET ONCOLOGY, 2021, 22 (02): : 223 - 234
12345